PADOPORFIN

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C35H36N4O6.Pd
Molecular Weight	715.1
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Pd++].CC[C@@H]1[C@@H](C)C2=CC3=C(C(C)=O)C(C)=C([N-]3)C=C4N=C([C@@H](CCC(O)=O)[C@@H]4C)C5=C6[N-]C(=CC1=N2)C(C)=C6C(=O)[C@@H]5C(=O)OC

InChI

InChIKey=GPIVNYFDHQDTDZ-GDUCSYRESA-L

InChI=1S/C35H38N4O6.Pd/c1-8-19-14(2)21-13-26-28(18(6)40)16(4)23(37-26)11-22-15(3)20(9-10-27(41)42)32(38-22)30-31(35(44)45-7)34(43)29-17(5)24(39-33(29)30)12-25(19)36-21;/h11-15,19-20,31H,8-10H2,1-7H3,(H3,36,37,38,39,40,41,42,43);/q;+2/p-2/t14-,15+,19-,20+,31-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	C35H37N4O6
Molecular Weight	609.6915
Charge	-1
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	Pd
Molecular Weight	106.42
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27019798 | https://clinicaltrials.gov/ct2/show/NCT01875393 | https://eg.uc.pt/bitstream/10316/29825/1/Development%20of%20a%20novel%20photosensitizer%20for%20Photodynamic%20Therapy%20of%20cancer.pdf

Padoporfin (palladium bacteriopheophorbide, also known as WST-09) from the bacteriopheophorbide family was used as a photosensitizer in clinical trials for prostate and kidney cancers. Padoporfin successfully completed phase III clinical trial where was shown its efficacy and safety for localized prostate cancer. Padoporfin is a powerful photosensitizer that produces photodynamic therapy effects similar to those seen with longer acting drugs, but with the major advantages of a short drug-light interval and rapid clearance.

Approval Year

PubMed

Title	Date	PubMed
Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses.	2008 Aug 5	18494829
Vascular targeted photochemotherapy using padoporfin and padeliporfin as a method of the focal treatment of localised prostate cancer - clinician's insight.	2016 Mar 26	27019798

Sample Use Guides

In Vivo Use Guide

Twenty-eight patients enrolled in this trial received a padoporfin dose of 2 mg/kg and a specific radiation fluence (λ = 763 nm), established in computer-assisted treatment plan

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Fri Dec 15 19:38:46 GMT 2023` Edited by `admin` on `Fri Dec 15 19:38:46 GMT 2023`
Record UNII	OIH1H7CJCJ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PADOPORFIN

Official Name

English

WST-09

Code

English

padoporfin [INN]

Common Name

English

WST09

Code

English

(HYDROGEN 3-((22R,7R,8R,17S,18S)-12-ACETYL-7-ETHYL-22-(METHOXYCARBONYL)-3,8,13,17-TETRAMETHYL-21-OXO-21,22,7,8,17,18-HEXAHYDROCYCLOPENTA(AT)PORPHYRIN-18-YL)PROPANOATO-K4N21,N22,N23,N24)PALLADIUM

Common Name

English

PALLADATE(1-), ((3S,4S,13R,14R,21R)-9-ACETYL-14-ETHYL-13,14-DIHYDRO-21-(METHOXYCARBONYL)-4,8,13,18-TETRAMETHYL-20-OXO-3-PHORBINEPROPANOATO(3-)-.KAPPA.N23,.KAPPA.N24,.KAPPA.N25,.KAPPA.N26)-, HYDROGEN (1:1), (SP-4-2)-

Systematic Name

English

TOOKAD

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1420